SCHEMBL5714635

SCHEMBL5714635

O=C(O)Cc1ccc(N2CCN(C(=O)Oc3ccc(CCSc4ccncc4)cc3)CC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 1/20 0.42
ME2 P23368 7/20 0.41
ME1 P48163 7/20 0.41
ME3 Q16798 7/20 0.41
GPR119 Q8TDV5 1/20 0.40
AOC3 Q16853 1/20 0.39
ALDH1A1 P00352 7/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP2C9 P11712 3/20 0.38
TSHR P16473 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPK1 P28482 2/20 0.38
CYP2C19 P33261 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
KDM4E B2RXH2 3/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714815 0.89 HRH3 (0.42) PANK3ME2ME1ME3GPR119
SCHEMBL5714729 0.88 ME2 (0.46) PANK3ME2ME1ME3GPR119
SCHEMBL5715446 0.88 PANK3 (0.44) PANK3ME2ME1ME3GPR119
SCHEMBL5714517 0.88 ME2 (0.46) PANK3ME2ME1ME3GPR119
SCHEMBL5714828 0.88 ME2 (0.47) PANK3ME2ME1ME3GPR119
SCHEMBL5904372 0.87 PANK3 (0.40) PANK3ME2ME1ME3GPR119
SCHEMBL5714407 0.86 HSD17B10 (0.46) PANK3ME2ME1ME3ALDH1A1
SCHEMBL5714344 0.86 SMN1; SMN2 (0.54) ALDH1A1CYP2C9SMN1; SMN2CYP1A2CYP2C19
SCHEMBL5714398 0.85 ALDH1A1 (0.52) ALDH1A1HSD17B10CYP2C9TSHRSMN1; SMN2
SCHEMBL5904278 0.84 PANK3 (0.41) PANK3ME2ME1ME3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885ME2 854/4885ME1 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.